Welcome to this website!

(+86)- 755 8670 3119 sales@senovatech.com

FOCUS ON NEW GENERICS AND ADVANCED INTERMEDIATES.

SERVE INNOVATION OF PHARMACEUTICALS.

SERVICE OF DMF/CMC PREPARATION AND PRE-AUDIT.

HIGH LEVEL R&D TEAM WITH GMP FACTORY.

PRODUCTS

ABOUT US

Welcome to Senova Technology Co., Ltd., a company founded in 2016, SENOVA means “SERVE INNOVATION", we focus on serving innovation in pharmaceuticals and related field mainly includes drug discovery, new compound research(includes Impurity Standard, advanced intermediates and key starting materials(KSM) supplying. Our products can meet customers' demand from small quantity (Gram grade) to bulk quantity (Tons grade) and secure the process under GLP/GMP regulation. Our customer includes pharmaceutical formulators, APIs Manufacturers and New Drugs Developers. We constantly making efforts to be a reliable and qualified partners of our esteemed customers. + ,MORE

OUR ADVANTAGES

GLOBAL BUSINESS

GLOBAL BUSINESS

We offer our customers from around the world to maintain a very good communication and product support services.

EFFICIENT LOGISTICS

xxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

FRIENDLY SUPPORT

FRIENDLY SUPPORT

To provide a quick reliable, responsive and cost effective service, in order to meet the needs of our service users.

HIGH QUALITY

HIGH QUALITY

Every product supplied from us is companied with COA (certificate of analysis), HPLC spectrum and NMR spectrum; and we give 15 days quality claim time for each of our product

WELL PACKAGE

WELL PACKAGE

We use best and professional material package to secure all products could be well packed and safe in the shipment from our warehouse to customers’ warehouse

FAST DELIVERY

FAST DELIVERY

We choose reliable and best service express companies and forwarders to deliver the goods to customers

Our customers

We help more than 3000 global customers -- over 30% leading brands in the world -- putting customers at their center.

阿里巴巴
推特
脸书
雅虎
中国制造网

NEWS

  • Gilead’s Vemlidy Hep B Drug Approved In EU (GILD)

    Gilead Sciences Inc. (GILD) secured marketing authorization from the European Commission for its hepatitis B drug Vemlidy. The oral medicine will be available in once-daily tablets of 25 mg, and will be suitable + 更多

  • Venetoclax Approved by FDA

    On April 11, 2016, the U. S. Food and Drug Administration approved venetoclax (VENCLEXTA tablets, marketed by AbbVie, Inc. and Genentech USA, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) wi...+ 更多

FAQ

问答标题测试测试

问答标题测试测试问答标题测试测试问答标题测试测试问答标题测试测试问答标题测试测试问答标题测试测试问答...+ 更多

WhatsApp

QQ

Mail to us